The results met expectations, holding below pre-pandemic levels.
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis
VANCOUVER, BC, Dec. 22, 2021 /CNW/ – Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending the Special Access Programme (SAP) to allow physicians to request patient access to psychedelic treatments, such as MDMA- and psilocybin-assisted therapy, for serious treatment-resistant or life-threatening conditions on a case-by-case basis. The amendment has the potential to positively affect the lives of people experiencing serious mental health conditions when other therapies have failed, are unsuitable or are unavailable in Canada.
"Amending the SAP and righting a historical wrong based on stigma highlights Canada's commitment to making psychedelic-assisted therapies a possibility for the many Canadians who struggle with mental wellness," said Payton Nyquvest, Founder and CEO, Numinus. "While we believe this is only the beginning of greater change to come, it signifies an important step towards creating expanded safe access to treatment and care in the mental health sector through psychedelic medicine. I am proud of our team who have had a longstanding role in advocating for this reform."
Health Canada's amendment recognizes a growing body of research, including the work that Numinus' clinical and research teams are completing, that has consistently shown the efficacy of psychedelic-assisted psychotherapy to treat a broad range of mental health conditions that are currently extremely difficult to treat with conventional therapies. According to Health Canada, access will be provided when there is sufficient data to support the safety and efficacy of the drug for the specific condition of the patient and will be available once the regulations come into force when the amendment is published in the Canada Gazette, which is anticipated on January 5th, 2022.
"Revising the SAP to allow for a case-by-case consideration of the suitability of psychedelic-assisted psychotherapy is a critical first step towards patients having access to these potentially transformative, safe and effective treatments when other treatments have failed," said Dr. Lindsay Farrell, Vice President of Indigenous Initiatives and Reconciliation, Numinus. "Nevertheless, new pathways ensuring equitable access to psychedelic-assisted therapies for racialized, marginalized, underserved populations and Indigenous Peoples are also urgently needed, especially in the context of sacred plants that have been used in cultural practices by Indigenous Peoples since Time Immemorial. We encourage the federal government to create regulations that acknowledge and honour the traditional use of certain sacred plants and create pathways for safe and equitable access." .
Added Dr. Evan Wood, Chief Medical Officer, Numinus: "We applaud Health Canada and hope this is the first in a series of regulatory reforms where the federal government can provide leadership with the best interests of Canadians in mind. We know that, with all currently illegal drugs, doing nothing only creates public and patient safety concerns that can best be addressed by thoughtful regulatory approaches."
The Special Access Programme (SAP)
The SAP was designed to allow people access to new, potentially life-saving medications before they are formally approved for routine use in healthcare.
Historically, psychedelic medications have been ineligible for Special Access Programme applications. The regulatory amendment, which is expected to come into force on January 5th, 2022, will enable Canadian physicians to apply for psychedelic therapies in a similar process as to how other investigational medications are accessed prior to formal drug approval.
A substantial body of research, including the completion of a growing number of randomized clinical trials, has demonstrated that psychedelic-assisted therapies using psilocybin and MDMA appear to be highly effective approaches for the treatment of a host of potentially life-threatening mental health conditions, including treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders, and severe anxiety associated with terminal diagnoses.
In addition to allowing ongoing access for research participants after a clinical trial is complete, the SAP enables physicians to apply for access on behalf of qualifying Canadians who have serious or life-threatening conditions.
Patients cannot apply to the SAP directly, and only licensed healthcare practitioners who are authorized under the laws of a province or territory to treat patients with a prescription drug may file requests through the SAP.
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", , "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this news release.
View original content:https://www.prnewswire.com/news-releases/numinus-wellness-commends-health-canada-on-special-access-programme-amendments-to-restore-potential-access-to-psychedelic-medicines-301450137.html
SOURCE Numinus Wellness Inc.
View original content: http://www.newswire.ca/en/releases/archive/December2021/22/c7446.html
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against the Omicron variant as well as additional data from its ongoing Phase 2 boost study. New results demonstrate broad cross-reactivity against Omicron and other circulating variants from a primary 2-dose regimen, with responses that increase
Allakos has deep pockets, but its market cap now is roughly equal to its $500 million or so in cash, and it has a new 10-year, $69-per-square-foot lease on its books in San Carlos.
What happened Shares of Moderna (NASDAQ: MRNA) fell 6.3% on Wednesday after the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Pfizer's (NYSE: PFE) oral COVID-19 treatment, Paxlovid.
What happened Shares of Teladoc Health (NYSE: TDOC) were falling 3.2% as of 2:42 p.m. ET on Wednesday. The decline appeared to be linked to reduced concerns about the impact of the coronavirus omicron variant.
Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. It plans to resubmit its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin), as a treatment for hallucinations and delusions associated with dementia. The company said it planned the resubmission, based on clinical data, for the first quarter of next year.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
US drugstore chains CVS and Walgreens are limiting the number of rapid at-home covid-19 test individual customers can buy at one time, in response to a surge in demand ahead of the holidays. With covid infections once again on the rise, likely due to the omicron variant, Americans have scrambled to purchase over-the-counter tests. “We ask that our customers please show patience and understanding as together, we continue to navigate the evolving pandemic environment,” Walgreens president John Standley said yesterday (Dec. 21).
The small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year.
Aquestive Therapeutics (NASDAQ: AQST) was one of the steeper decliners among biotech stocks Tuesday. The company's shares plummeted more than 29% on a rather discouraging piece of news about one of its top drug candidates. Late Monday night, Aquestive disclosed that it had received notification from the Food and Drug Administration (FDA) regarding its Libervant Buccal Film pipeline drug.
The United States authorized Pfizer’s pill to fight covid Wednesday, making it the first oral, at-home treatment for the coronavirus… in what doctors hope is an important tool in the fight against the fast-spreading Omicron variant. Pfizer's antiviral regimen was 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness. AND Recent lab data suggests the drug retains its effectiveness against Omicron. White House COVID-19 Response Coordinator Jeff Zients: “As we've done with vaccines and monoclonals we'll distribute these treatments, these pills in a fair and equitable way now that they've been authorized by the FDA. The antivirals will be provided to states and jurisdictions at no charge on a pro-rata basis to quickly – to get that supply in the field. As I mentioned in my comments, as part of the administration's commitment to equity, we are also distributing antiviral pills, Pfizer directly to federally qualified community health centers across all 50 states.” The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant.The most widely used monoclonal antibody treatments for COVID-19 – which are typically given intravenously in hospitals – have proven to be less effective at fighting the variant and doctors told Reuters there is limited supply of the one remaining treatment that works.The hope is that the Pfizer pill fills the gap. Pfizer said it is ready to start immediate delivery in the U.S. and raised its production projections to 120 million courses of treatment in 2022.
Hospitals’ highest rates often go to rental networks of healthcare providers that are sometimes used in limited-benefits plans, according to a Wall Street Journal analysis. The combination can leave patients with especially high bills.
Is Pfizer stock a buy as the FDA reportedly nears a decision on its Covid antiviral pill? Is PFE stock a buy right now?
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral suspension) for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form. Related content: Benzinga's Full FDA Calendar. In addition, the FDA recommended an additional clinical study to hel
Tuesday was the Winter Solstice, our darkest day and longest night before the sun begins its slow ascent higher into the sky again.
The Paxlovid pill is the first Covid-19 drug cleared in the U.S. that newly infected patients can now take at home to stay out of the hospital.
In 2020, most people had to cancel their vacation plans because of the COVID pandemic. But this year, travel has picked back up dramatically thanks to vaccinations and ongoing mask requirements. For the past two months, airports in the U.S. have seen upwards of two million passengers pass through each day, according to the Transportation Security Administration (TSA). That's a sharp increase from the 500,000 to 900,000 air travelers seen each day at this same time last year. Unfortunately, a hig
In a year when the Covid-19 pandemic and its variants were mostly kept at bay by the Bay — relative to other parts of the country at least — the biotech and health news flow didn't slow. Here's a quick look at the stories that made the cut: With a $575 million IPO in April, Zymergen Inc. (NASDAQ: ZY) was the poster child for synthetic biology. Suffice it to say, I thank my colleague Cromwell Schubarth for falling on the sword of the Elizabeth Holmes fraud trial.
According to the CDC guidelines, those who test positive, regardless of vaccination status, must isolate for 10 days.
If you’ve stocked up on salad ahead of the holidays, you should ensure that the products you’ve purchased have not been just recalled. One company recalled certain types of salad on suspicion of Salmonella contamination a few days ago. That was a limited recall that only impacted products sold in Canada. On top of that, … The post Massive salad recall: If you have these salads in your fridge, throw them out appeared first on BGR.
German health experts said on Wednesday that new coronavirus curbs probably did not go far enough to keep the Omicron variant in check, as the country's health minister said he had not ruled out a full lockdown if cases spiked. The measures, decided on Tuesday, include limits on private gatherings, closing clubs and discos and banning spectators at football matches and are set to be introduced from Dec. 28. Janosch Dahmen, health expert for junior coalition partners the Greens, said they were a step in the right direction.